Polpharma Biologics integrates Dutch based subsidiary, Bioceros, to offer the complete spectrum of services from discovery to commercial supply.
Gdansk, Poland and Utrecht, The Netherlands 13th July 2020. In 2016, Polpharma Biologics acquired Dutch based Biocero…
On Demand Webinar: Looking to develop a high quality, high titer manufacturing cell line?
We have developed our SPOT™ technology alongside our proprietary CHO cell line to increase the cell line specific pro…
All hands on deck! We all fight with COVID-19
The current situation caused by COVID-19 concerns us all. We had decided to help because we care. That’s why we have…
Bioceros develops monoclonal antibodies as a division of Polpharma Biologics Group
Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros C…
First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.
Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medicat…
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine
Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a nat…
32nd International Symposium on Preparative and Process Chromatography in Baltimore
We participated in the 32nd International Symposium on Preparative and Process Chromatography in Baltimore.
Launching of the 4th edition of the Career Laboratory!
We are starting recruitment for the 4th edition of our Career Laboratory internship program.
Meet us at BIO-Europe Spring in Vienna!
Polpharma Biologics participates in 13th annual BIO-Europe Spring conference in Vienna (Austria).
Inauguration of the second edition of the BIO Academy (BIO Akademia)
Polpharma Biologics invests in the practical education of its employees in the field of biotechnology.